Inhibikase Therapeutics Announces FDA has... - Cure Parkinson's

Cure Parkinson's

26,584 members27,904 posts

Inhibikase Therapeutics Announces FDA has Lifted the Full Clinical Hold on IkT-148009 in Parkinson's Disease

3 Replies

inhibikase.com/news/press-r...

"We are grateful for the expeditious review by the FDA of our response to the Clinical Hold on IkT-148009 in PD," stated Milton H. Werner, Ph.D., President and Chief Executive Officer of Inhibikase Therapeutics. "We believe that we now have clarity on the FDA's expectations as we move forward in the 201 clinical trial for IkT-148009. We are now working to re-open clinical trial sites and initiate screening and enrollment of patients for the trial following agreed upon updates to the Protocol and Informed Consent form. We anticipate completing these restart tasks by the end of the first quarter."

Read more about...
3 Replies
jimcaster profile image
jimcaster

Good news!

WinnieThePoo profile image
WinnieThePoo in reply tojimcaster

For my 401K you mean 🤣

WinnieThePoo profile image
WinnieThePoo

Thanks for sharing this. It reminds me why I keep coming back to this forum

Not what you're looking for?

You may also like...

Inhibikase Therapeutics Announces FDA Clinical Hold on IkT-148009 Programs

https://www.inhibikase.com/news/press-releases/detail/66/inhibikase-therapeutics-announces-fda-clini

Beyond Nilotinib: A next-generation c-Abl inhibitor from Inhibikase Therapeutics (IkT-148009) has reached clinical-trial stage (Phase 1b)

"The failure of Nilotinib to provide a clinically meaningful benefit in PD patients in two...
jeffreyn profile image

A (minor) update by Inhibikase Therapeutics on their Phase 2 trial of Risvodetinib (IkT-148009) for Parkinson's Disease.

As of 24 Feb 2024: - Recruitment continues and is reaching the halfway point (59 of 120); - 25...
jeffreyn profile image

ANNOVIS BIO ANNOUNCES POSITIVE FDA FEEDBACK FOR BUNTANETAP PHASE 3 CLINICAL DEVELOPMENT IN PARKINSON'S DISEASE (ANVS401)

https://irpages2.eqs.com/websites/annovis/English/431010/us-press-release.html?releaseID=111474&d=20

Potential disease-modifying therapy enters Phase 2

"Following the review of the data of the 101 trial, the drug advanced to the Phase II 201 trial...